Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?

The prognosis of patients with metastatic melanoma has substantially improved over the last years with the advent of novel treatment strategies, mainly immune checkpoint inhibitors and BRAF and MEK inhibitors. Given the survival benefit provided in the metastatic setting and the evidence from prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Indini, Alice, Roila, Fausto, Grossi, Francesco, Massi, Daniela, Mandalà, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200339/
https://www.ncbi.nlm.nih.gov/pubmed/34036489
http://dx.doi.org/10.1007/s40257-021-00608-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200339/
https://www.ncbi.nlm.nih.gov/pubmed/34036489
http://dx.doi.org/10.1007/s40257-021-00608-5

Ejemplares similares